NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ESPR Stock Alerts $2.12 +0.03 (+1.44%) (As of 01:58 PM ET) Add Compare Share Share Today's Range$2.06▼$2.1650-Day Range$1.84▼$3.2452-Week Range$0.70▼$3.40Volume3.98 million shsAverage Volume6.72 million shsMarket Capitalization$401.53 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Esperion Therapeutics alerts: Email Address Esperion Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside340.3% Upside$9.33 Price TargetShort InterestBearish11.82% of Float Sold ShortDividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment1.20Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.68) to $0.31 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.70 out of 5 starsMedical Sector206th out of 909 stocksPharmaceutical Preparations Industry84th out of 423 stocks 3.2 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.82% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Esperion Therapeutics has recently increased by 12.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 3.4 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Esperion Therapeutics this week, compared to 2 articles on an average week.Search Interest76 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 192% compared to the previous 30 days.MarketBeat FollowsOnly 22 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -4% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.68) to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Esperion Therapeutics Stock (NASDAQ:ESPR)Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More ESPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESPR Stock News HeadlinesApril 23, 2024 | finance.yahoo.comEsperion to Report First Quarter 2024 Financial Results on May 7April 21, 2024 | finance.yahoo.com11 Best Low Price Pharma Stocks To Invest InApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 20, 2024 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Hold" from AnalystsApril 8, 2024 | msn.comEsperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groupsApril 7, 2024 | globenewswire.comEsperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityApril 3, 2024 | msn.comSignet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On WednesdayApril 1, 2024 | globenewswire.comEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 26, 2024 | finance.yahoo.comEsperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceMarch 26, 2024 | msn.comWhy Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?March 25, 2024 | globenewswire.comEsperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24March 25, 2024 | msn.comEsperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market SessionMarch 23, 2024 | money.usnews.comEsperion Therapeutics Inc.March 22, 2024 | finance.yahoo.comU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | businesswire.comU.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | globenewswire.comU.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | marketwatch.comEsperion Therapeutics Gets CHMP Positive Opinion for Cholesterol MedicationsMarch 22, 2024 | globenewswire.comCHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsMarch 14, 2024 | msn.comTerns to report Phase 1 data on GLP-1 drug in 2H 2024March 4, 2024 | finance.yahoo.com11 Best Small Cap Pharma Stocks to Invest InFebruary 28, 2024 | seekingalpha.comA Relief Earnings Report Ahead Of An Inflection Point For Esperion TherapeuticsFebruary 28, 2024 | finance.yahoo.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comQ4 2023 Esperion Therapeutics Inc Earnings CallFebruary 27, 2024 | seekingalpha.comEsperion Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | finanznachrichten.deEsperion Therapeutics, Inc.: Esperion Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | finance.yahoo.comEsperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023See More Headlines Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/24/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+346.6%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,250,000.00 Net Margins-179.87% Pretax Margin-179.87% Return on EquityN/A Return on Assets-91.62% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio0.87 Sales & Book Value Annual Sales$116.33 million Price / Sales3.40 Cash FlowN/A Price / Cash FlowN/A Book Value($3.85) per share Price / Book-0.54Miscellaneous Outstanding Shares189,400,000Free Float187,507,000Market Cap$395.85 million OptionableOptionable Beta0.84 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Sheldon L. Koenig (Age 58)President, CEO & Director Comp: $1.2MMr. Benjamin O. Looker (Age 42)General Counsel Comp: $550.35kDr. JoAnne Micale Foody FACC (Age 58)M.D., Chief Medical Officer Comp: $771.19kMr. Benjamin Halladay M.B.A. (Age 38)Chief Financial Officer Mr. Glenn P. Brame (Age 66)Chief Technical Operations Officer Tiffany Aldrich M.B.A.Associate Director of Corporate CommunicationsMs. Betty Jean SwartzChief Business OfficerMr. Eric J. Warren R.Ph. (Age 52)Chief Commercial Officer More ExecutivesKey CompetitorsCorbus PharmaceuticalsNASDAQ:CRBPBiomea FusionNASDAQ:BMEAOrganogenesisNASDAQ:ORGOAnnexonNASDAQ:ANNXNeurogeneNASDAQ:NGNEView All CompetitorsInsiders & InstitutionsHerbst Group LLCBought 10,300 shares on 4/23/2024Ownership: 0.005%Wasatch Advisors LPBought 238,544 shares on 4/18/2024Ownership: 4.820%Capital Advisors Wealth Management LLCBought 21,800 shares on 4/12/2024Ownership: 0.012%Nomura Holdings Inc.Sold 78,676 shares on 3/27/2024Ownership: 0.020%Chicago Partners Investment Group LLCSold 14,433 shares on 2/23/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions ESPR Stock Analysis - Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View ESPR analyst ratings or view top-rated stocks. What is Esperion Therapeutics' stock price target for 2024? 5 Wall Street research analysts have issued twelve-month price objectives for Esperion Therapeutics' stock. Their ESPR share price targets range from $4.00 to $16.00. On average, they expect the company's stock price to reach $9.33 in the next twelve months. This suggests a possible upside of 340.3% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts. How have ESPR shares performed in 2024? Esperion Therapeutics' stock was trading at $2.99 at the beginning of 2024. Since then, ESPR stock has decreased by 29.1% and is now trading at $2.12. View the best growth stocks for 2024 here. Are investors shorting Esperion Therapeutics? Esperion Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 19,920,000 shares, an increase of 12.7% from the March 15th total of 17,670,000 shares. Based on an average daily volume of 6,710,000 shares, the short-interest ratio is presently 3.0 days. Approximately 11.8% of the shares of the company are sold short. View Esperion Therapeutics' Short Interest. When is Esperion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ESPR earnings forecast. How can I listen to Esperion Therapeutics' earnings call? Esperion Therapeutics will be holding an earnings conference call on Tuesday, May 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.03. The biopharmaceutical company had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same period in the previous year, the firm posted ($0.76) EPS. What ETFs hold Esperion Therapeutics' stock? ETFs with the largest weight of Esperion Therapeutics (NASDAQ:ESPR) stock in their portfolio include Jacob Forward ETF (JFWD).Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors LP (4.82%), Capital Advisors Wealth Management LLC (0.01%) and Herbst Group LLC (0.01%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ESPR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
